TFF Pharmaceuticals (TFFP) Set to Announce Earnings on Wednesday

TFF Pharmaceuticals (NASDAQ:TFFPGet Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, May 11th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

TFF Pharmaceuticals (NASDAQ:TFFPGet Rating) last released its earnings results on Thursday, March 24th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.10). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.94 million. TFF Pharmaceuticals had a negative return on equity of 61.58% and a negative net margin of 35,272.73%. During the same quarter in the previous year, the firm earned ($0.26) EPS. On average, analysts expect TFF Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:TFFP opened at $5.11 on Wednesday. The business has a 50 day moving average of $6.21 and a 200 day moving average of $6.91. The company has a market capitalization of $129.65 million, a price-to-earnings ratio of -4.09 and a beta of 2.14. TFF Pharmaceuticals has a 1-year low of $4.80 and a 1-year high of $12.28.

In other news, Director Aaron G.L. Fletcher purchased 542,000 shares of TFF Pharmaceuticals stock in a transaction that occurred on Monday, April 4th. The shares were bought at an average cost of $6.47 per share, with a total value of $3,506,740.00. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at $647,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 9.90% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TFFP. Goldman Sachs Group Inc. purchased a new stake in shares of TFF Pharmaceuticals in the fourth quarter worth $118,000. Stifel Financial Corp grew its stake in shares of TFF Pharmaceuticals by 31.8% in the fourth quarter. Stifel Financial Corp now owns 14,500 shares of the company’s stock worth $129,000 after acquiring an additional 3,500 shares during the last quarter. Morgan Stanley grew its stake in shares of TFF Pharmaceuticals by 2,166.9% in the first quarter. Morgan Stanley now owns 17,206 shares of the company’s stock worth $233,000 after acquiring an additional 16,447 shares during the last quarter. State Street Corp grew its stake in shares of TFF Pharmaceuticals by 47.4% in the fourth quarter. State Street Corp now owns 64,678 shares of the company’s stock worth $574,000 after acquiring an additional 20,800 shares during the last quarter. Finally, UBS Group AG grew its stake in shares of TFF Pharmaceuticals by 1,456.1% in the third quarter. UBS Group AG now owns 79,798 shares of the company’s stock worth $616,000 after acquiring an additional 74,670 shares during the last quarter. 18.28% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently weighed in on TFFP shares. Zacks Investment Research downgraded TFF Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 30th. B. Riley dropped their target price on TFF Pharmaceuticals from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, March 29th.

About TFF Pharmaceuticals (Get Rating)

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Recommended Stories

Earnings History for TFF Pharmaceuticals (NASDAQ:TFFP)

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.